Viewing Study NCT02145403

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:33 PM
Ignite Modification Date: 2026-03-05 @ 3:30 AM
Study NCT ID: NCT02145403
Status: COMPLETED
Last Update Posted: 2022-01-03
First Post: 2014-05-20
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
Sponsor: University of Michigan Rogel Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Hematologic Malignancies View
None Relapse View
None Graft-Versus-Host Disease View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Allogeneic Transplantation View
None Carfilzomib View
None Relapse View
None Graft-Versus-Host Disease View
None Multiple Myeloma View
None Lymphoma View
None Leukemia View